Johns Hopkins Kimmel Cancer Center researchers say preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Imatinib mesylate (Gleevec). Gleevec, one of the first targeted cancer therapies with wide success in CML patients, destroys most leukemic cells in the ...